Product Liability
Oct. 21, 2015
Date set for failure-to-warn trial over antipsychotic drugs
The first of more than 3,200 coordinated failure to warn cases against Johnson & Johnson and Janssen Pharmaceuticals over antipsychotics Risperdal and Invega will take place June 13, 2016 in Los Angeles County Superior Court, attorneys said Monday. Plaintiffs allege the drugs caused the development of breasts in men and boys.
Daily Journal Staff Writer
The first trial of more than 3,200 coordinated failure-to- warn cases against Johnson & Johnson and Janssen Pharmaceuticals Inc. for the antipsychotics Risperdal and Invega will take place June 13, 2016 before Los Angeles County Superior Court Judge William F. Highberger, attorneys said Monday.
Plaintiffs allege that the drugs, prescribed for schizophrenia and bipolar disorder in adults b...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In